Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies

Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a v...

Descripción completa

Detalles Bibliográficos
Autores principales: Grassadonia, Antonino, Cioffi, Pasquale, Simiele, Felice, Iezzi, Laura, Zilli, Marinella, Natoli, Clara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2013
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795372/
https://www.ncbi.nlm.nih.gov/pubmed/24202327
http://dx.doi.org/10.3390/cancers5030919
_version_ 1782287370490478592
author Grassadonia, Antonino
Cioffi, Pasquale
Simiele, Felice
Iezzi, Laura
Zilli, Marinella
Natoli, Clara
author_facet Grassadonia, Antonino
Cioffi, Pasquale
Simiele, Felice
Iezzi, Laura
Zilli, Marinella
Natoli, Clara
author_sort Grassadonia, Antonino
collection PubMed
description Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms.
format Online
Article
Text
id pubmed-3795372
institution National Center for Biotechnology Information
language English
publishDate 2013
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-37953722013-10-21 Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies Grassadonia, Antonino Cioffi, Pasquale Simiele, Felice Iezzi, Laura Zilli, Marinella Natoli, Clara Cancers (Basel) Review Hydroxamate-based histone deacetylase inhibitors (Hb-HDACIs), such as vorinostat, belinostat and panobinostat, have been previously shown to have a wide range of activity in hematologic malignancies such as cutaneous T-cell lymphoma and multiple myeloma. Recent data show that they synergize with a variety of cytotoxic and molecular targeted agents in many different solid tumors, including breast, prostate, pancreatic, lung and ovarian cancer. Hb-HDACIs have a quite good toxicity profile and are now being tested in phase I and II clinical trials in solid tumors with promising results in selected neoplasms, such as hepatocarcinoma. This review will focus on their clinical activity and safety in patients with advanced solid neoplasms. MDPI 2013-07-25 /pmc/articles/PMC3795372/ /pubmed/24202327 http://dx.doi.org/10.3390/cancers5030919 Text en © 2013 by the authors; licensee MDPI, Basel, Switzerland. http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Grassadonia, Antonino
Cioffi, Pasquale
Simiele, Felice
Iezzi, Laura
Zilli, Marinella
Natoli, Clara
Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
title Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
title_full Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
title_fullStr Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
title_full_unstemmed Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
title_short Role of Hydroxamate-Based Histone Deacetylase Inhibitors (Hb-HDACIs) in the Treatment of Solid Malignancies
title_sort role of hydroxamate-based histone deacetylase inhibitors (hb-hdacis) in the treatment of solid malignancies
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3795372/
https://www.ncbi.nlm.nih.gov/pubmed/24202327
http://dx.doi.org/10.3390/cancers5030919
work_keys_str_mv AT grassadoniaantonino roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies
AT cioffipasquale roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies
AT simielefelice roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies
AT iezzilaura roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies
AT zillimarinella roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies
AT natoliclara roleofhydroxamatebasedhistonedeacetylaseinhibitorshbhdacisinthetreatmentofsolidmalignancies

Ejemplares similares